KNSA Kiniksa Pharmaceuticals, Ltd. Stock Quote

KNSA [NASD]

Index	-	P/E	-	EPS (ttm)	-2.37	Insider Own	6.18%	Shs Outstand	65.96M	Perf Week	-2.47%
Market Cap	1.28B	Forward P/E	-	EPS next Y	-2.80	Insider Trans	-5.88%	Shs Float	29.67M	Perf Month	8.05%
Income	-139.50M	PEG	-	EPS next Q	-0.62	Inst Own	87.50%	Short Float	13.58%	Perf Quarter	5.12%
Sales	-	P/S	-	EPS this Y	-43.60%	Inst Trans	-1.74%	Short Ratio	11.11	Perf Half Y	-1.84%
Book/sh	5.44	P/B	3.62	EPS next Y	-15.20%	ROA	-49.10%	Target Price	-	Perf Year	36.09%
Cash/sh	5.60	P/C	3.52	EPS next 5Y	-	ROE	-53.70%	52W Range	10.30 - 28.67	Perf YTD	11.60%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-31.22%	Beta	-
Dividend %	-	Quick Ratio	15.20	Sales past 5Y	-	Gross Margin	-	52W Low	91.46%	ATR	1.36
Employees	135	Current Ratio	15.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	56.15	Volatility	8.89% 7.19%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-34.70%	Profit Margin	-	Rel Volume	0.99	Prev Close	19.77
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	362.76K	Price	19.72
Recom	1.60	SMA20	6.95%	SMA50	9.92%	SMA200	3.25%	Volume	359,817	Change	-0.25%

Jun-29-20

Reiterated

BofA Securities

Buy

$25 → $40

Apr-01-20

Initiated

BofA/Merrill

Buy

$25

Mar-11-19

Initiated

Barclays

Overweight

$26

Dec-12-18

Reiterated

Wedbush

Outperform

$31 → $33

Jun-19-18

Initiated

JMP Securities

Mkt Outperform

$33

Jan-11-21 08:00AM	Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones GlobeNewswire
Jan-04-21 04:20PM	Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-22-20 08:00AM	Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation GlobeNewswire
Dec-18-20 08:51AM	Is KNSA A Good Stock To Buy Now? Insider Monkey
Dec-15-20 08:00AM	Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis GlobeNewswire
Nov-30-20 08:00AM	Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404 GlobeNewswire
Nov-24-20 08:00AM	Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire +9.87%
Nov-23-20 08:00AM	Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis GlobeNewswire
Nov-17-20 08:00AM	Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020 GlobeNewswire
Nov-16-20 08:00AM	Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis GlobeNewswire
Nov-10-20 09:15AM	Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation Simply Wall St.
Nov-09-20 04:01PM	Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data GlobeNewswire
Nov-05-20 07:30AM	Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity GlobeNewswire
Oct-29-20 08:00AM	Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis to be Presented at European Academy of Dermatology and Venereology Virtual Congress GlobeNewswire
Oct-26-20 08:00AM	Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020 GlobeNewswire
Oct-14-20 09:54PM	Hedge Funds Are Starting To Get Bullish On Kiniksa Pharmaceuticals, Ltd. (KNSA) Insider Monkey -5.87%
Oct-07-20 10:14AM	Company News for Oct 7, 2020 Zacks
Oct-06-20 08:00AM	Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis GlobeNewswire +18.31%
Sep-24-20 04:12PM	Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th GlobeNewswire
Sep-21-20 08:00AM	Kiniksa Announces Upcoming Rilonacept Analyst Day GlobeNewswire -8.53%
Sep-15-20 08:00AM	Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis GlobeNewswire +5.22%
Sep-09-20 04:01PM	Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference GlobeNewswire
Aug-31-20 08:00AM	Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020 GlobeNewswire +6.99%
Aug-04-20 08:00AM	Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-30-20 07:30AM	Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity GlobeNewswire
Jul-28-20 03:42PM	Do Insiders Own Lots Of Shares In Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)? Simply Wall St.
Jul-21-20 09:55PM	Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering GlobeNewswire -9.34%
Jul-20-20 04:07PM	Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering GlobeNewswire
Jul-16-20 07:30AM	Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis GlobeNewswire
Jul-08-20 12:53PM	J.P. Morgan Says These 3 Stocks Will Surge Over 30% From Current Levels TipRanks
Jul-05-20 11:03PM	Hedge Funds Are Betting On Kiniksa Pharmaceuticals, Ltd. (KNSA) Insider Monkey
Jun-30-20 09:56AM	Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group Zacks
09:35AM	Company News for Jun 30, 2020 Zacks
Jun-29-20 03:47PM	3 Strong Buy Coronavirus Stocks With Massive Upside Potential TipRanks +12.90%
10:48AM	Kiniksa Reports Positive Results of Pericarditis-Drug Trial TheStreet.com
08:09AM	5 Stocks With Recent Price Strength Amid Spike in Coronavirus Zacks
07:15AM	Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY) GlobeNewswire
Jun-17-20 08:00AM	Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19 GlobeNewswire
Jun-12-20 10:43AM	Zacks.com featured highlights include: SunOpta, eXp World, Calix, Kiniksa Pharmaceuticals and iClick Interactive Asia Group Zacks
Jun-10-20 08:00AM	Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts GlobeNewswire +5.16%
Jun-08-20 08:00AM	Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial GlobeNewswire +11.32%
Jun-04-20 08:00AM	Kiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare Conference GlobeNewswire
May-29-20 08:30AM	Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020 GlobeNewswire
May-22-20 08:56AM	How Kiniksa Pharmaceuticals (KNSA) Stock Stands Out in a Strong Industry Zacks
May-18-20 04:01PM	Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
May-13-20 11:12PM	Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering GlobeNewswire -10.13%
05:12PM	Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering GlobeNewswire
May-11-20 07:30AM	Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus GlobeNewswire +9.30%
May-06-20 11:43AM	Will Kiniksa Pharmaceuticals Continue to Surge Higher? Zacks
Apr-28-20 07:30AM	Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity GlobeNewswire
Apr-22-20 08:00AM	Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint GlobeNewswire
Apr-08-20 11:30AM	Has Kiniksa Pharmaceuticals (KNSA) Outpaced Other Medical Stocks This Year? Zacks
Apr-06-20 07:45PM	Coronavirus Stocks Gain: Vir Biotech up 26.6%; Kiniksa off 0.7% TheStreet.com
08:29AM	3 Healthcare Stocks Fighting the Coronavirus TipRanks
Apr-01-20 09:04AM	Company News for Apr 1, 2020 Zacks
Mar-31-20 08:15AM	Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation GlobeNewswire +26.68%
Mar-30-20 07:30AM	Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session GlobeNewswire
Feb-26-20 07:30AM	Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity GlobeNewswire
Feb-11-20 09:12AM	Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance Zacks
Feb-05-20 09:21AM	Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat Zacks
Jan-13-20 08:00AM	Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts GlobeNewswire
Dec-19-19 10:13AM	The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals Zacks
Dec-18-19 02:27PM	Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More Zacks
Dec-16-19 07:29AM	Did Hedge Funds Drop The Ball On Kiniksa Pharmaceuticals, Ltd. (KNSA) ? Insider Monkey
Dec-12-19 09:59AM	Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy Zacks
Dec-11-19 09:47AM	Goldman Sachs: The Good, the Bad and the Ugly of the Biotech Sector TipRanks
08:30AM	Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma GlobeNewswire
Dec-10-19 08:00AM	Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire +13.63%
Dec-07-19 07:07AM	We're Keeping An Eye On Kiniksa Pharmaceuticals's (NASDAQ:KNSA) Cash Burn Rate Simply Wall St.
Nov-21-19 10:22AM	Company News For Nov 21, 2019 Zacks
Nov-20-19 04:01PM	Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference GlobeNewswire +28.67%
08:00AM	Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis GlobeNewswire
Nov-16-19 12:00PM	Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 GlobeNewswire
Nov-12-19 04:01PM	Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting GlobeNewswire -7.91%
Nov-01-19 10:55AM	Were Hedge Funds Right About Selling Kiniksa Pharmaceuticals, Ltd. (KNSA)? Insider Monkey +5.82%
Oct-28-19 04:01PM	Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity GlobeNewswire
Oct-08-19 04:48AM	Kiniksa Pharmaceuticals Enters Oversold Territory Zacks
Sep-19-19 04:01PM	Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research GlobeNewswire
Aug-19-19 07:30AM	Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 GlobeNewswire
Aug-12-19 04:02PM	Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity GlobeNewswire
04:01PM	Kiniksa Announces Interim Data from KPL-716 Repeated-Single-Dose Phase 1b Clinical Trial GlobeNewswire
Aug-06-19 07:30AM	Kiniksa Pharmaceuticals to Present at the 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-05-19 07:30AM	Kiniksa Pharmaceuticals Announces Collaboration with the Myocarditis Foundation for the Pericarditis Community GlobeNewswire
Jun-29-19 06:17PM	Is Kiniksa Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ? Insider Monkey
Jun-12-19 07:30AM	Kiniksa Presents Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at the Annual European Congress of Rheumatology GlobeNewswire
Jun-10-19 11:26AM	The Kiniksa Pharmaceuticals (NASDAQ:KNSA) Share Price Is Down 23% So Some Shareholders Are Getting Worried Simply Wall St.
May-30-19 04:01PM	Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019 GlobeNewswire
May-29-19 04:01PM	Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
May-16-19 07:30AM	Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research GlobeNewswire
May-13-19 07:30AM	Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology GlobeNewswire
May-02-19 07:30AM	Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity GlobeNewswire
Apr-29-19 02:55PM	Is Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ? Insider Monkey
Apr-23-19 06:00AM	Long-Term "GameChangers" in Biotech MoneyShow
Apr-17-19 04:25PM	Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology GlobeNewswire
Apr-08-19 04:01PM	Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs GlobeNewswire -10.59%
Mar-18-19 07:30AM	Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiologys 68th Annual Scientific Session GlobeNewswire
Mar-07-19 07:30AM	Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity GlobeNewswire
Feb-28-19 07:30AM	Kiniksa Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference GlobeNewswire
Feb-26-19 07:30AM	Kiniksa Pharmaceuticals to Present at the Barclays Global Healthcare Conference GlobeNewswire
Jan-31-19 08:57AM	Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering GlobeNewswire

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and in Phase 1a clinical trial for the treatment of atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate investigational combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Sanj K	Chairman & CEO	Oct 12	Option Exercise	1.59	150,700	239,613	150,700	Oct 14 05:22 PM
Patel Sanj K	Chairman & CEO	Oct 12	Sale	21.02	99,330	2,087,917	112,570	Oct 14 05:22 PM
Patel Sanj K	Chairman & CEO	Oct 12	Sale	21.02	150,700	3,167,714	0	Oct 14 05:22 PM
Patel Sanj K	Chairman & CEO	Oct 09	Option Exercise	1.59	872	1,386	872	Oct 14 05:22 PM
Patel Sanj K	Chairman & CEO	Oct 09	Sale	21.00	670	14,070	211,900	Oct 14 05:22 PM
Patel Sanj K	Chairman & CEO	Oct 09	Sale	21.00	872	18,312	0	Oct 14 05:22 PM
Beetham Thomas W.	EVP & Chief Legal Officer	Jul 01	Sale	25.37	29,589	750,678	0	Jul 02 04:13 PM
Beetham Thomas W.	EVP & Chief Legal Officer	Jun 10	Option Exercise	1.59	13,752	21,866	43,341	Jun 12 05:50 PM
Beetham Thomas W.	EVP & Chief Legal Officer	Jun 10	Sale	25.07	13,752	344,763	29,589	Jun 12 05:50 PM
Beetham Thomas W.	EVP & Chief Legal Officer	Apr 21	Sale	19.89	2,518	50,092	29,589	Apr 22 05:39 PM
Beetham Thomas W.	EVP & Chief Legal Officer	Apr 20	Sale	19.06	47,423	903,882	32,107	Apr 22 05:39 PM
Patel Sanj K	Chairman & CEO	Mar 06	Sale	20.00	33,115	662,300	212,570	Mar 10 05:33 PM
Paolini John F.	SVP & Chief Medical Officer	Feb 27	Option Exercise	1.86	12,000	22,320	30,000	Mar 02 05:48 PM
Paolini John F.	SVP & Chief Medical Officer	Feb 20	Option Exercise	3.80	9,803	37,251	27,803	Feb 21 04:57 PM
Paolini John F.	SVP & Chief Medical Officer	Feb 20	Sale	18.96	9,803	185,832	18,000	Feb 21 04:57 PM
Paolini John F.	SVP & Chief Medical Officer	Feb 19	Option Exercise	3.80	22,477	85,413	40,477	Feb 21 04:57 PM
Paolini John F.	SVP & Chief Medical Officer	Feb 19	Sale	18.27	22,477	410,655	18,000	Feb 21 04:57 PM
Paolini John F.	SVP & Chief Medical Officer	Feb 14	Option Exercise	3.80	1,039	3,948	19,039	Feb 18 06:05 PM
Beetham Thomas W.	EVP & Chief Legal Officer	Feb 14	Sale	18.58	59	1,096	79,530	Feb 19 05:24 PM
Paolini John F.	SVP & Chief Medical Officer	Feb 14	Sale	18.33	1,039	19,045	18,000	Feb 18 06:05 PM
Paolini John F.	SVP & Chief Medical Officer	Feb 13	Option Exercise	3.80	10,277	39,053	28,277	Feb 18 06:05 PM
Paolini John F.	SVP & Chief Medical Officer	Feb 13	Sale	18.29	10,277	187,966	18,000	Feb 18 06:05 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience